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Background. Emerging data relating to human immunodeﬁciency virus type 1 (HIV-1) cure suggest that vac-
cination to stimulate the host immune response, particularly cytotoxic cells, may be critical to clearing of reactivated
HIV-1–infected cells. However, evidence for this approach in humans is lacking, and parameters required for a vac-
cine are unknown because opportunities to study HIV-1 reactivation are rare.
Methods. We present observations from a HIV-1 elite controller, not treated with combination antiretroviral
therapy, who experienced viral reactivation following treatment for myeloma with melphalan and autologous
stem cell transplantation. Mathematical modeling was performed using a standard viral dynamic model. Enzyme-
linked immunospot, intracellular cytokine staining, and tetramer staining were performed on peripheral blood
mononuclear cells; in vitro CD8 T-cell–mediated control of virion production by autologous CD4 T cells was quan-
tiﬁed; and neutralizing antibody titers were measured.
Results. Viral rebound was measured at 28 000 copies/mL on day 13 post-transplant before rapid decay to
<50 copies/mL in 2 distinct phases with t1/2 of 0.71 days and 4.1 days. These kinetics were consistent with an expan-
sion of cytotoxic effector cells and killing of productively infected CD4 T cells. Following transplantation, innate
immune cells, including natural killer cells, recovered with virus rebound. However, most striking was the expansion
of highly functional HIV-1–speciﬁc cytotoxic CD8 T cells, at numbers consistent with those applied in modeling, as
virus control was regained.
Conclusions. These observations provide evidence that the human immune response is capable of controlling
coordinated global HIV-1 reactivation, remarkably with potency equivalent to combination antiretroviral therapy.
These data will inform design of vaccines for use in HIV-1 curative interventions.
Keywords. elite control; HIV; cure; CD8; myeloablation.
To date, the “Berlin patient”isthe only known human im-
munodeﬁciency virus type 1 (HIV-1)–infected individual
to achieve sustained nondetectable viremia without re-
bound following removal of combination antiretroviral
therapy (cART). This success is likely due to a combi-
nation of transplantation with cells from a donor who
lacked the chemokine (C-C motif) receptor 5 HIV-1
coreceptor that limited HIV-1 propagation, total body
irradiation that depleted existing latently infected
cells, and graft vs host disease. These observations
have sparked the search for novel approaches to clear
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 HIV reservoirs that reside largely in resting memory CD4+ T
cells.
Recently, Shan et al, using an in vitro model of HIV latency,
observed that HIV-1 reactivation was not itself adequate to de-
stroy infected cells but that coculture with antigen-stimulated
CD8 T cells could clear reactivated cells. This suggeststhat in ad-
dition to strategies that reactivate HIV latently infected CD4 T
cells, future cure approaches may also need to stimulate immune
responses, for example, through vaccination [1].
Thehostimmuneresponseplaysaclearroleinmaintenanceof
virus load (VL) control in HIV-1 infection. The clearest example
ofthiscan befound inHIV-1–infectedindividualswhomaintain
VL <50 copies/mL without receiving cART (approximately 0.3%
of HIV-1–infected individuals). These individuals, termed elite
controllers (ECs), control acute HIV-1 viremia within weeks to
months of infection [2], have higher CD4 T-cell counts than
non-ECs, and progress far more slowly to AIDS [3]. CD8
T cells have been implicated in HIV-1 control in ECs largely be-
cause of enrichment of certain major histocompatibility com-
plex class I alleles (human leucocyte antigen [HLA]-B*57,
HLA-B*27, HLA-B*81) that are also associated with lower VLs
and slower disease progression [4–8].Protection in these individ-
ualsisthoughttobelargelymediated bythe inductionofHIV-1–
speciﬁc CD8 T cells restricted predominantly by these HLA al-
leles. Mapping of these “protective” CD8 T-cell responses in ECs
demonstrates that they typically target more conserved regions of
HIV-1, commonly within the Gag protein. During chronic infec-
tion, HIV-1–reactive CD8 T-cell responses restricted by protec-
tive HLA are normally very strong or immunodominant within
the individual. HIV mutation and escape from CD8 T-cell re-
sponses, when detected, have been associated with subsequent
disease progression [9–11]. Further evidence of the role of
CD8+ T cells comes from studies of macaques in which removal
of anti–simian immunodeﬁciency virus (SIV) CD8+ T cells dur-
ing acute infection and chronic infection resulted in loss of virus
control, with control regained as CD8+ T cells returned [12–15].
Recent reports have highlighted the fact that elite virus control
does not equate to HIV cure. ECs exhibit ongoing inﬂammation
and innate immune activation, and have lower CD4 counts rela-
tive to uninfected individuals [16].These symptoms are, in part,
driven by residual levels of virus, with recent studies showing that
cART can reduce inﬂammation in ECs [17]. This leavesthe ques-
tion of how well the immune response in chronically infected in-
dividuals, even in ECs, could respond to a coordinated global
reactivation ofthe HIV reservoir proposed in HIV cure strategies.
In this study, we report a HIV-1–infected, antiretroviral ther-
apy (ART)-naive EC who was treated for refractory myeloma
with myeloablation and an autologous stem cell transplant
(ASCT). Shortly after treatment, HIV-1 reactivation to 28 000
copies/mL was observed followed by rapid control of viremia to
<50 copies/mL, remarkably at rates comparable to ART. This
patient represents the ﬁrst example of post-transplantation con-
straint of a large-scale virus reactivation mediated by the human
immune response, presenting an unprecedented opportunity to
measure both kinetics and in vitro correlates of efﬁcacy.
METHODS
Total DNA Polymerase Chain Reaction
The duplexed polymerase chain reaction (PCR) was performed
using 600 ng of patient template DNAwith forward and reverse
primer pairs for pyruvate dehydrogenase (PDH), PDH probe,
long terminal repeat (LTR), and LTR probe. PCR was per-
formed using Qiagen Multiplex Mastermix at 95°C for 15 min-
utes followed by 50 cycles at 94°C for 1 minute and 60°C for 1
minute. Assays were carried out in triplicate, and results were
expressed as total HIV DNA copies per million cells.
CD8 T-Cell Antiviral Assay (Extracellular p24)
The assay was performed as previously described [18].
ELISpot for Interferon-γ Secreting Peripheral Blood
Mononuclear Cell
T-cell epitopes were initially mapped against proteome-wide
consensus clade C peptides (overlapping 15–18mers) in inter-
feron-gamma (IFN-γ) ELISpot using peripheral blood mono-
nuclear cells (PBMCs) collected at day 336. Peptides were
then tested in triplicate at days 41 and 42 as previously de-
scribed [19], and optimal epitopes were deﬁned. Positive T-
cell responses were 4× background and >30 spot forming
units/10
6 cells following background subtraction [20].
Intracellular Cytokine and Tetramer Staining
See Supplementary materials for details.
Flow Cytometry of Lymphocyte Cells
See Supplementary materials for details.
Mathematical Modeling
A standard viral dynamic model [21] of HIV infection and ef-
fector cell responses was analyzed and represented as a system
of differential equations (see Supplementary materials)t h a t
were then solved numerically using Berkeley Madonna v8.3.18.
RESULTS
A 59-year-old HIV-1 EC was treated for refractory myeloma
using melphalan-induced myeloblation followed by an ASCT
totaling 1.9×10
10 cells. The ASCT contained both CD34
stem cells and mature lymphoid cells. The patient received eto-
poside–methylprednisolone–cytarabine–cisplatin conditioning
and granulocyte colony-stimulating factor (CSF) to mobilize
stem cells to the periphery. ART was not given in view of
2 ￿ CID ￿ HIV/AIDS
 
a
t
 
U
n
i
v
e
r
s
i
t
y
 
C
o
l
l
e
g
e
 
L
o
n
d
o
n
 
o
n
 
M
a
y
 
2
7
,
 
2
0
1
5
h
t
t
p
:
/
/
c
i
d
.
o
x
f
o
r
d
j
o
u
r
n
a
l
s
.
o
r
g
/
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 undetectable VL and concerns regarding drug toxicity. The
melphalan treatment precipitated neutropenia and lymphope-
nia at +6 days (Supplementary Figure 1), at which time the
HIV-1 VL had rebounded to 17000 copies/mL (Figure 1A).
At +13 days the lymphocyte count had increased to 1280
cells/mm
3 and VL was 28000 copies/mL (Figure 1A). The
post-transplant environment contains high levels of interleu-
kin-7 (IL-7) and IL-15, known to support homeostatic prolifer-
ation of memory, largely effector T cells, and may promote
reactivation of HIV-1 from latently infected cells [22]. Consis-
tently, CD4 T cells in this patient in the weeks following reacti-
vation (day +21, day +42) exhibited a largely effector phenotype
(Figure 1B). Cells showed elevated activation, as measured by
CD38 and programmed death 1 (PD1) staining and increased
Ki67 staining (Figure 1C,T a b l e1), without change in cell
surface CD4 levels (data not shown), providing conditions con-
ducive to HIV-1 reactivation and propagation.
The VL rebound doubling time was 0.5 days, similar to that
observed in acute infection (0.65 days) [23]. Importantly, the
observation conﬁrms that this EC harbored a fully replica-
tion-competent virus. This was followed by a VL decay charac-
terized by 2 phases (Figure 1A), the ﬁrst with t1/2 of 0.7 days and
the second with t1/2 of 4.1 days. This ﬁrst rate was derived from
2 measurements and therefore is subject to greater measure-
ment error. We therefore incorporated the intraassay variability
of the clinical VL test (1.9 fold), as determined by replicate mea-
surements against known standards in our calculations. This
produced an estimate of ﬁrst phase t1/2 of 0.49–1.27 days. Com-
parison of these calculated rates with those described following
ART treatment showed that the average ﬁrst phase t1/2 of
Figure 1. Dynamic changes in human immunodeﬁciency virus (HIV) viremia and CD4 T-cell activation levels following transplantation of CD34-enriched
peripheral blood stem cells (day 0). A, Plasma HIV-1 RNA (copies/mL; blue circles), total lymphocyte count (×10
3/mm
3; red squares), and total viral DNA
(HIV-1 copies/million peripheral blood mononuclear cells [PBMCs]; black triangles) over time following reinfusion of stem cells demonstrating ﬁrst and
second phase decay (dotted lines). Dashed line represents the lower limit of detection of the HIV-1 RNA viral load assay (50 copies/mL plasma). Note:
The ﬁrst HIV DNA measurement was below the limit of detection and has been plotted at 10 copies due to limitations of a logarithmic scale. Cytotoxic
chemotherapy was administered at day 1. B, Frequency of CD4 naive and memory subsets over time: Tcm =central (CD45RO+CD27+) memory, Tem =
effector (CD45RO+CD27−) memory (C). The frequency of CD38 (red) and PD1 (blue) on CD4 T lymphocytes following stem cell infusion relative to plasma
virus loads (black spheres). Inserts in (B) and (C) show cell subset frequencies in the pretreatment leukapheresis sample (autologous stem cell transplant
[ASCT]).
HIV/AIDS ￿ CID ￿ 3
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 0.7 days was very similar to a published estimate for the most
potent cART [24]. The second phase t1/2 of 4.1 days was
signiﬁcantly shorter than previous published estimates of
14.25 (99% conﬁdence interval, 4.780–23.370), derived using
less potent antiretroviral combinations [25]. The measured
peak in plasma VL RNA was accompanied by a rise in total
HIV-1 DNA levels in PBMC from <10 copies/10
6 cells pre-
melphalan treatment to 127 copies/10
6 cells at day +13, before
subsequent decay with a t1/2 of 3.8 days (black triangles,
Figure 1A).
By day +37, the VL had declined to undetectable levels. Dur-
ing the observed VL decline (day +13 to day +37), CD4 T-cell
counts were >300 cells/mm
3 (Figure 1A) compared with a total
lymphocyte count of 70 cells/ mm
3at day +6. Therefore, limited
target cell availability is unlikely to have accounted for the VL
decline. These cell kinetics were consistent with review of the
terminal half-lives of the patient’s pre-transplant conditioning
regimens that suggested that the drugs received were unlikely to
have impacted immune cell viability and function in the post-
transplant environment (Supplementary text I). The patient
achieved a favorable response to myeloma treatment and was
in a stable plateau phase at +472 days.
The ASCT, when compared with the subsequent stage of du-
rable virus control and normal ranges of lymphocyte subsets
(data not shown), had diminished numbers of B, natural killer
(NK), and NKT cells whereas T-cell numbers were overrepre-
sented, consistent with the effects of CSFs prior to the harvest
(Table 1)[ 22]. The kinetics of lymphocyte populations during
virus rebound were also consistent with those of immune recov-
ery post-transplantation including HIV-1–infected patients [22,
26].This included increases in frequencies of NK subsets within
weeks of transplant as well as a striking expansion of CD8+
Tc e l l s( T a b l e1). CD19+ B cells did not recover until after
virus control had been regained (Table 1). Neutralizing antibody
titers were modest (Supplementary Table 1)i nc o m p a r i s o nt ot i -
ters commonly seen in chronic HIV-1 infection of viremic pa-
tients and individuals undergoing ART interruption [27, 28]
and therefore are unlikely to have contributed to the control
observed.
We used mathematical modeling [21] to determine whether
the patient’s unique HIV-1 viral kinetics and cell death rates
were consistent with established models of cytolytic immune
cell viral control. A standard viral dynamic model, shown sche-
maticallyinFigure2A, wasanalyzedinwhich infectedcells inthe
eclipse phase, I1, transition to productive infection, I2, and with
both populations as well as long-lived infected cells, M*, being
potential targets of immune cell killing. In the model, cytolytic
effectors, E, were stimulated by the presence of infected cells
and grew with saturating kinetics. The model was represented
asa system ofdifferentialequations and solvednumerically (Sup-
plementary material). The model was able to reproduce the VL
changes observed in the patient (Figure 2B). Furthermore, by
changing parameters, we were able to explore the effects of the
different biological processes being modeled. We found that
with parameters that resulted in a VL peak at about day 8, the
effector cells that started at a low precursor frequency were still
sufﬁcient to expand rapidly near the peak VL and reproduce
the viral load decline kinetics we observed (Figure 2B).
We determined whether HIV-1–speciﬁc CD8 T-cell respons-
es were dominating the observed control. Although PBMCs
prior to melphalan treatment were unavailable, we did have
access to the ASCT taken 41 days before transplantation. We as-
sumed that these cells were the baseline sample as they repre-
sented the major source of memory T cells at day 0. Mapping
of HIV-1–speciﬁc T-cell responses identiﬁed epitopes in Gag
and Pol detectable in the baseline and at subsequent time points
(Figure 3A). Direct virus sequencing showed no amino acid
changes in anyof the Gag or Pol CD8 T-cell–restricted epitopes,
indicating no virus escape from T cells during the study period
(+472 days from transplantation; data not shown).
Focusing on the dominant HLA-B*81–restricted TL9 and
LY9 Gag-speciﬁc responses, we examined IFN-γ, tumor necro-
sisfactor-alpha(TNF-α),andIL-2productionandexpressionof
Table 1. Changes in Lymphocyte Populations From Autologous
Stem Cell Transplant to Resolution of Viremia
Days Post-Transplant
−41 21 42 472
Viral load <50 940 <50 <50
Percentage of live lymphocytes
NK cells (CD56+)
a 0.18 1.51 1.58 2.29
Of which CD16+CD56bright ND 0.68 2.69 2.20
Of which CD16+CD56dim ND 77.7 84.8 81.4
Of which CD16−CD56bright ND 1.02 2.28 4.00
Of which CD16−CD56dim ND 22.6 11.2 0.00
NKT-like cells (CD3+CD56+) 2.30 3.27 2.01 1.59
CD3 T cells (CD3+CD56−) 92.8 86.4 96.0 88.6
CD8 T cells (CD3+CD8+) 23.4 69.1 74.1 46.5
B cells (CD3−CD19+) 0.00 0.06 0.12 2.25
Proliferation: % Ki67+
NK cells 92.5 92.1 81.5 10.5
NKT cells 58.3 63.0 75.3 3.20
CD8+ T cells 100 99.7 99.8 1.62
CD4+ T cells (CD3+CD8−CD56−) 90.9 90.5 99.0 1.77
B cells ND 50.0 39.5 4.24
Lymphocyte populations were assessed by flow cytometry and are shown as a
percentage of the total live cells (as determined by an amine-reactive viability
dye) present in each sample. Autologous stem cells for day −41 or peripheral
blood mononuclear cell for days 21,42, and 472.
Abbreviations: ND, not determined due to too few cells in the parent gate for
analysis; NK, natural killer.
a Defining markers for each population are shown in brackets.
4 ￿ CID ￿ HIV/AIDS
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 CD107a+ lytic granules by intracellularcytokine ﬂow cytometry
before (−41 days), during (+21 days), and after (+42 and +212
days) viral rebound. Very similar functional patterns were ob-
served for both epitopes: 65% of baseline speciﬁc T cells exhib-
ited >1 function and almost 20% exhibited triple IFN-γ, TNF-α,
and CD107a expression following stimulation (Figure 3B).
These proportions are consistent with functional proﬁles of
HIV viremic controllers who exhibit broader CD8 T-cell func-
tionality than viremic progressors [7]. During virus rebound
(day 21), the proportion of single positive, largely IFN-γ
or CD107a positive, cells increased in both the TL9- and
LY9-speciﬁc populations by around 3-fold. By day 212, the
functional phenotype of both cell populations was very similar
to that observed at baseline. Analysis of the total measured
functional T-cell response (at least 1 function) found that the
TL9- and LY9-speciﬁc cells accounted for 2% of total memory
CD8+ T cells in the baseline sample (Figure 3C), equating to
approximately 26 million cells transferred in the ASCT (details
presented in the “Methods” section). Upon virus reactivation,
the TL9-speciﬁc functional T-cell response increased >4-fold
(Figure 3C), and parallel HLA-B*81-TL9 tetramer staining
showed that almost 16% of circulating memory CD8 T cells
were speciﬁc following rebound (Figure 3D). TL9 reactive
cells exhibited a CD45RO+CD27+ central memory phenotype
(data not shown), and CD38 and PD1 staining showed that cells
were highly activated around peak virus rebound. In contrast,
CD57 levels, which are a hallmark of extensive cellular division,
were stable during virus rebound (Figure 3E). These T-cell fre-
quencies (Figure 3A), when combined with the high, absolute
CD8 T-cell counts measured post-HIV reactivation (Figure 1),
were consistent with the “effector” numbers that yielded virus
control in our modeling analysis (Figure 2B).
We quantiﬁed the ability of the patient’s CD8 T cells to limit
virus production following infection of autologous T cells with
an HIV laboratory isolate. Fresh CD8 T cells isolated following
control of HIV-1 viremia (days +326 and +354) reduced HIV-1
p24 derived from autologous CD4 T cells by 3 orders of mag-
nitude by day 7 in culture (Figure 4A and 4B). We then estimat-
ed the in vitro t1/2 for virus inhibition. When autologous CD4
cells were infected in vitro, supernatant p24 increased at a rate
of 0.75/day. In contrast, in the presence of autologous CD8 T
cells at a 1:1 ratio, p24 decreased at a rate of 0.75/day, translating
to a t1/2 of 0.93 days, which is similar to the rates of VL decline
observed in vivo (Figure 1A).
DISCUSSION
Emerging data from laboratory studies relating to HIV-1 cure
suggest that vaccination to stimulate the host immune response,
particularly cytotoxic cells, may be critical to the clearing of re-
activated HIV-1–infected cells following use oflatency reversing
agents (LRAs). However, evidence for this approach in humans
is lacking, and parameters required for a vaccine are unknown
because opportunitiesto study HIV-1 reactivation are extremely
rare. We combined in vivo, in silico, and in vitro approaches to
demonstrate for the ﬁrst time that the human immune response
Figure 2. Mathematical modeling is consistent with CD8+ T-cell–medi-
ated killing of infected cells. A, Schematic illustration of mathematical
model. On the left, cells M, which might be macrophages or resting
CD4+ T cells, when infected by human immunodeﬁciency virus type 1
(HIV-1), V, become long-lived infected cells, M*, which are estimated to
be responsible for a few percent of body-wide viral production [25]. The
cells on the right, T, are the major targets of HIV infection. After infection,
the cells, I1, are in an eclipse phase and do not produce virus until they
transition into productively infected cells, I2. Both I2 and M cells produce
virus, V. This free virus can, in turn, infect uninfected target cells, T and M.
When effector cells, E, contact infected cells they become activated, re-
sulting in both killing of the infected target and proliferation of the effector
cell. The model also considers the death rates of cells and the viral clear-
ance rate. B, Resultsof simulating the modelgiven byEq.(1) detailed in the
Supplementary text; HIV-1 RNA/mL (green) and effector cells/ mL (blue).
Parameters used are as follows: r=0.8 d
−1, β=1.66×10
−8 mL d
−1, βM=
4.14 ×10
−9 mL d
−1, dT =0.5 d
−1, Tmax =10
6/mL, t1 =6d,M =6×10
4/mL,
δ =0.9d
−1, δE1 =0.01mLd
−1, δE2=0.001 mL d
−1, δEM* =10
−4 mL d
−1,
δM=0 .0 1d
−1, k=1.0 d
−1, q=0. 2d
−1, K=1,p=2 00 00d
−1, pM= 200 d
−1,
and c=2 3d
−1. The initial conditions were T(0)= 6× 10
5 /mL, I1(0)=I2(0)=
M*(0)= 0, E(0)= 0.05/mL, and V(0)=10/mL. The viral loads generated
by the model agreewith the ones measured in the patient (open circles).
The magnitude of the effector cell response is also consistent in mag-
nitude to the measured level of HIV-1–speciﬁc CD8 T-cell responses at
day 42 shown in Figure 3.
HIV/AIDS ￿ CID ￿ 5
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 Figure 3. Human immunodeﬁciency virus type 1 (HIV-1)–speciﬁc CD8+ T-cell responses are highly functional, expanding strongly with control of HIV-1
reactivation. T-cell responses were initially mapped by interferon-gamma (IFN-γ) enzyme-linked immunospot at +336 days and were reﬁned to optimal
epitopes based on the patient’s human leukocyte antigen type. A, IFN-γ responses to mapped peptides were assayed in the baseline sample and peripheral
blood mononuclear cells (PBMCs) at +42 days post-transplantation. Results represent mean±standard deviation spot forming units/10
6 cells of triplicate
measurements. B, Functionality of TL9 and LY9 CD8 memory T-cell responses before (−41 days, viral load [VL] <50), during (+21 days, VL measured at +19
and +23 days was 940 and 650 copies/mL, respectively), and after (+42 and +212 days, VL<50) virus rebound. Colored arcs indicate cytokines. Shaded
sectors show the proportion of each cytokine combination. C, Gag 180–188 (TL9) and Gag 78–86 (LY9) T-cell responses measured by intracellular cytokine
ﬂow cytometry prior to and during VL rebound. Percentage of CD8+ memory T cells expressing 1 or more of IFN-γ, tumor necrosis factor (TNF)-alpha,
interleukin-2 (IL-2), and CD107a, as well as IFN-γ only, shown. D, Kinetics of B*81:01 Gag180–188 tetramer+ cells and VL during the study period. E,
Changes in expression of activation markers CD57, PD-1, and CD38 by tetramer+ CD8 memory T cells during VL decline. Note: PBMCs prior to chemotherapy
were unavailable; however, a sample from the leukapheresis at day −41 that wastransplanted at day 0 was considered to be a baseline and representative
of HIV-1–speciﬁc T-cell responses prior to chemotherapy.
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 is capable of controlling an iatrogenic large-scale HIV-1 reacti-
vation, as might be induced by LRAs.
The datawere derived from a HIV-1 seropositive EC who un-
derwent myeloablation and ASCT as treatment for myeloma.
The patient rapidly regained control of viral reactivation with
kinetics comparable to those previously observed with ART.
Our primary observation was the rapid rate of virus decline in
the patient from day 13 to day 37 post-transplant. A biphasic
decline was observed: the ﬁrst slope, though derived from lim-
ited measurements, had a t1/2 of 0.71 (0.49–1.27) days and was
equivalent to that observed in the most potent ART regimens.
Notably, the higher estimate of 1.27 days was still classiﬁed as
rapid in the absence of therapyand very similar to the estimated
t1/2 of HIV-1 in post-peak virus decline in acute viremia [23].
The t1/2 in the second phase was 4.7 days, also comparable to
observations in ART-treated patients.
In the absence ofART, what parameters produced these slopes
in the patient? First, analysis of virus kinetics found that the virus
upslopewas more rapid than that observed in acute viremia [23].
This suggested that the rebounding virus in this EC was highly
competent for replication in vivo, and therefore the virus itself
couldnotexplainthedeclineobserved.Arecentreportalsoshowed
that virus isolates from ECs were fully replication-competent in
vivo usinga humanizedmicemodel ofHIV-1 infection [29].Sec-
ond, in the pre-ART era, HIV-1–infected noncontrollers under-
going similar myeloablation and transplantation procedures
consistently exhibited high viremia post-transplant, indicating
that the conditioning regimens do not, when used alone, con-
strain HIV-1 replication [30]. Further, analysis of pharmacoki-
netic data of the patient’s conditioning regimens indicated that
theywereunlikelytoimpactcellviability,whichisconsistentwith
the patient’s CD4 T cell count, which remained >300 cells/mm
3
as VL control was regained. In summary, the VL kinetics in the
patient are not explained by poor virus replication nor limiting
target cell availability.
During this rebound period, the patient’s HIV-1–speciﬁc
CD8 T-cell response expanded strongly. This occurred in re-
sponse to HIV-1 reactivation and was unlikely a by-product
of homeostatic proliferation. In macaques, IL-15 treatment of
durably suppressed SIV-infected monkeys similarly induced
homeostatic proliferation of CD4 and CD8 effector T-cell sub-
s e t sb u td i dn o ti n c r e a s eS I V - s p e c i ﬁc T-cell responses [31].
T-cell mapping showed that in the patient, the immunodomi-
nant CD8 T-cell epitope corresponded to the dominant T-cell
response observed in HLA-B*81:01 patients. This T-cell re-
sponse has been detected in patients with acute HIV-1 infec-
tion, including those who subsequently achieved elite control.
The target epitope is highly conserved at the population level,
and subsequent escape is associated with signiﬁcant loss of rep-
licative ﬁtness [20, 32]. We followed the kinetics of the domi-
nant T-cell responses and found strong expansion in response
tovirus rebound, though without evidence that cells were termi-
nally expanded. These cell populations rapidly declined follow-
ing reacquisition of virus control. No virus escape through
mutation of T-cell epitopes was observed during the period of
study, consistent with T cells exerting an ongoing immune pres-
sure. Analysis of other CD8 T-cell functions during the rebound
period found that HIV-1–speciﬁc cells became highly activated
and, interestingly, appeared to exhibit reduced oligofunctional-
ity relative to HIV-1–speciﬁc cells analyzed at baseline. Activa-
tion levels rapidly subsided when virus control was regained,
with broader functionality in terms of cytokine and lytic marker
production again observed.
Last, strong in vitro suppression of HIV was observed at a
subsequent time point following virus control (when HIV-1–
speciﬁc CD8 T-cell frequencies were much lower). Importantly,
the frequencies of the patient’s HIV-1–speciﬁc T-cell responses,
Figure 4. Autologous CD8+ T cells potently suppress extracellular
human immunodeﬁciency virus type 1 (HIV-1). HIV-1 capsid p24 production
was measured using enzyme-linked immunosorbent assay in culture super-
natants (mean ±standard deviation, n =3) from elite controller-derived
CD4+ T cells (days 326, 354, and 383) infected with HIV-1 BaL (A), as
well as CD4+ T cells derived from chronically HIV-1–infected individuals
(n =3) (B) in the absence (closed) or presence (open symbols) of autologous
unstimulated CD8+ T cells (at ratio 1:1). Each experiment was performed in
triplicate, and data shown are representative of at least 2 independent
experiments.
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 when combined with the high, absolute CD8 T-cell counts mea-
sured post-HIV reactivation, were consistent with the “effector”
numbers in modeling that produced VL kinetics very similar to
that observed in our patient. Together, these data suggest that
the patient’s HIV-1–speciﬁc CD8 T-cell response following re-
activation directly contributed to the virus control observed.
This hypothesis is further supported by recent studies of vire-
m i cc o n t r o l l e rm a c a q u e si nw h i c hv i r u sr e b o u n df o l l o w i n g
CD8 depletion by antibodies and regain of virus control as
CD8 T cells returned were observed [14,15].Additional support
is garnered from the transplantation biology setting where
cytomegalovirus (CMV) reactivation is often observed post-
transplantation, with the level of CMV-reactive CD8 T cells cor-
relating with control of CMV viremia [33].
However, as a single patient study, our observations are asso-
ciative. We cannot quantify the precise in vivo contribution of
CD8 T cellsto the controlobserved and do notexclude a role for
other subsets, particularly NK cells, in this patient, contributing
either directly to anti–HIV-1 cytotoxicity or indirectly by con-
ferring a clinical beneﬁt against the patient’s myeloma [34].The
T-cell responses induced in this patient were typical of those in-
duced in other ECs, suggesting that vaccination regimens that
induce broadly functional CD8 T-cell responses, with good rep-
licative potential and targeting conserved regions of HIV-1,
might be more effective at recognizing and clearing reactivated
HIV-infected cells. However, challengesto this approach still re-
main, for example, the requirement for immune-boosting strat-
egies that target conserved, unmutated epitopes following the
recent ﬁnding that HIV-1 proviruses in latently infected cells
from chronically infected patients almost always contain cyto-
toxic T lymphocyte escape mutations [35].
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